FEG
FBLG icon

Fund Evaluation Group’s FibroBiologics FBLG Stock Holding History

Fund Evaluation Group’s Portfolio FBLG Stock Details FBLG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$49.1K Hold
51,794
– – ﹤0.01% 79
2026
Q1 		$68.4K Buy
+51,794
New +$308K ﹤0.01% 72

Other funds holding FBLG

CFP
Cascade Financial Partners San Diego, California $1.15B AUM 33.6% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Fund Evaluation Group's FBLG Position: Q2 2026 in Review

Fund Evaluation Group held its FibroBiologics (FBLG) position steady in Q2 2026 at 51,794 shares worth $49.1K. The position accounts for ﹤0.01% of the portfolio, ranked #79.

Fund Evaluation Group first reported a position in FBLG in Q1 2026 and has held it in 2 quarters since. The position peaked at $68.4K in Q1 2026. 16 funds tracked by Wall St. Rank hold FBLG as of Q2 2026.

  • Fund Evaluation Group held 51,794 shares of FibroBiologics worth $49.1K as of Q2 2026.
  • Fund Evaluation Group left its FibroBiologics share count unchanged in Q2 2026.
  • FibroBiologics made up ﹤0.01% of Fund Evaluation Group's portfolio in Q2 2026, its #79 holding.
  • Fund Evaluation Group first reported a position in FibroBiologics in Q1 2026 and has held it in 2 quarters since.
  • Fund Evaluation Group's FibroBiologics position peaked at $68.4K in Q1 2026.
  • 16 funds tracked by Wall St. Rank held FibroBiologics as of Q2 2026.

Based on Fund Evaluation Group's 13F filing for Q2 2026, filed 7 Aug 2026.